The latest price target for Viracta Therapeutics (NASDAQ:VIRX) was reported by Rodman & Renshaw on December 27, 2024. The analyst firm set a price target for $0.25 expecting VIRX to rise to within 12 months (a possible 52.63% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Viracta Therapeutics (NASDAQ:VIRX) was provided by Rodman & Renshaw, and Viracta Therapeutics downgraded their neutral rating.

There is no last upgrade for Viracta Therapeutics

The last downgrade for Viracta Therapeutics Inc happened on December 27, 2024 when Rodman & Renshaw changed their price target from $3.5 to $0.25 for Viracta Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viracta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viracta Therapeutics was filed on December 27, 2024 so you should expect the next rating to be made available sometime around December 27, 2025.

While ratings are subjective and will change, the latest Viracta Therapeutics (VIRX) rating was a downgraded with a price target of $3.50 to $0.25. The current price Viracta Therapeutics (VIRX) is trading at is $0.16, which is out of the analyst’s predicted range.